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CI = confidence interval; CVAP = cyclophosphamide, doxorubicin, vincristine and prednisolone; DFS = disease-free survival; ER = estrogen receptor;
HR = hazard ratio; PgR = progesterone receptor; TAC = docetaxel, doxorubicin and cyclophosphamide.
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Introduction
Clinicians and scientists from more than 80countries con-
vened in San Antonio, Texas on 3–6December 2003 for
the 26th annual San Antonio Breast Cancer Symposium.
The symposium was directed by C Kent Osborne and
Charles A Coltman, Jr. More than 6000attendees partici-
pated in the discussion and presentation of scientific
advances, which covered the entire spectrum of breast
cancer research including cellular and molecular biology,
etiology, prevention, diagnosis and treatment. The present
report will focus on the clinical highlights of the meeting.
Audiovisual highlights of the symposium are available elec-
tronically (http://www.sabcs.org) and abstracts are available
online (http://www.abstracts-on-line.com/abstracts/BCS/).
Optimal adjuvant hormonal therapy
Paul Goss, on behalf of the National Cancer Institute of
Canada Clinical Trials Group, presented the first evidence
that patients with hormone-sensitive, early-stage breast
cancer may benefit from sequential hormonal therapy. The
investigators randomized 5187postmenopausal women
who had completed 5years of adjuvant tamoxifen to either
letrozole or placebo [1]. At a median follow-up of
2.4years, the estimated 4-year disease-free survival (DFS)
was 93% in the letrozole group and 87% in the placebo
group (P=0.00008). This represents a 43% overall
reduction in the risk of recurrence. The toxicity assess-
ment showed increased hot flashes, arthralgias and myal-
gias in the letrozole-treated group and showed increased
vaginal bleeding in the placebo group. Patients treated
with letrozole had a trend toward a higher incidence of
new diagnoses of osteoporosis. Unfortunately, we do not
have information regarding the long-term toxicities of this
approach, and the study will not yield this information
since the majority of patients in the placebo arm have
elected to switch to letrozole therapy.
Francesco Boccardo (University of Genoa, Italy) presented
the results of a randomized study comparing adjuvant anas-
trozole after 2–3years of adjuvant tamoxifen with continued
tamoxifen. Both groups of patients were to receive a total of
5years of therapy. A total of 448patients with node-posi-
tive, estrogen receptor (ER)-positive disease enrolled. At a
median follow-up of 3years, patients switched to anastro-
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zole had fewer clinical events (17events) than patients
remaining on tamoxifen (45events). Clinical events included
local–regional recurrence, distant metastases, second
primary cancers (including endometrial cancer) and death
from any cause. Each type of clinical event was reduced in
the patients switched to anastrozole.
These two studies indicate that there may be benefit in
treating early-stage, hormonally responsive breast cancer
with sequential hormonal therapy. However, the sequences
studied to date are limited to tamoxifen followed by an aro-
matase inhibitor. Results from the Arimidex, Tamoxifen
Alone or in Combination trial have led many women to
receive adjuvant aromatase therapy as the initial treatment
[2,3]. Mitch Dowsett, on behalf of the Arimidex, Tamoxifen
Alone or in Combination investigators, presented an analy-
sis of time to recurrence in the Arimidex, Tamoxifen Alone
or in Combination trial according to ER and progesterone
receptor (PgR) status. At 47months of median follow-up,
the hazard ratio (HR) for DFS was 0.86 (95% confidence
interval [CI]=0.76–0.99, P=0.03) for the overall study
population and was 0.82 (95% CI=0.70–0.96, P=0.014)
in the ER-positive and/or PgR-positive group favoring anas-
trozole. However, the magnitude of benefit was influenced
by the ER and PgR status. The greatest reduction in risk
was seen in the ER-positive, PgR-negative group
(HR=0.48, 95% CI=0.33–0.71). This is statistically differ-
ent from the HR of 0.82 (95% CI=0.65–1.03) in the ER-
positive and PgR-positive group (P=0.05), and may be a
clue to the etiology of tamoxifen resistance.
Clinicians are challenged to predict which hormonal
therapy is the optimal adjuvant treatment for an individual
patient. Biomarkers are needed to predict responsive
disease. Ian Smith and Mitch Dowsett (Royal Marsden
Hospital, London, UK) presented data from the multicenter
Immediate Preoperative Arimidex Compared to Tamoxifen
(IMPACT) trial. This neoadjuvant trial randomized
330postmenopausal women with ER-positive, invasive,
operable breast cancer to receive 3months of preopera-
tive therapy with anastrozole, tamoxifen, or both. The trial
objectives included the assessment of clinical response,
the conversion of planned mastectomy to lumpectomy and
the assessment of biomarker modulation. While neoadju-
vant anastrozole allowed significantly more women previ-
ously judged to require a mastectomy to undergo
breast-conserving surgery than did tamoxifen (46% versus
22%, P=0.03), the overall response rates were not statis-
tically different (37% versus 36%). The subgroup of
patients with Her2-positive tumors was small (34
patients). However, these patients did have a higher
response rate with anastrozole therapy than with tamoxifen
(58% versus 22%).
Dowsett presented information regarding the impact of
neoadjuvant therapy on the modulation of the proliferation
marker Ki67. Two hundred and fifty-nine patients had tumor
specimens available for analysis corresponding to pretreat-
ment, 2 and 12weeks post initiation of treatment. Interest-
ingly, all three treatments (anastrozole, tamoxifen and their
combination) reduced Ki67 expression with maximal mean
reductions after only 2weeks of therapy. Anastrozole had a
significantly greater antiproliferative effect at both time
points than did tamoxifen (P<0.01) but the change in Ki67
did not correlate with response to therapy.
These interesting presentations challenge us with many
new questions regarding optimal adjuvant hormonal
therapy. The woman previously counseled that tamoxifen
was the ‘gold standard’ may now be offered 5years of
adjuvant anastrozole as an alternative and counseled that
anastrozole as compared with tamoxifen will result in a
further 18% reduction in the relative risk of relapse. Alter-
natively, planning sequential adjuvant hormonal therapy
may be best. Adjuvant tamoxifen followed by adjuvant
letrozole resulted in a 43% reduction in the relative risk of
recurrence in the study presented by Goss and col-
leagues [1]. Or possibly, the best alternative is 2–3years
of adjuvant tamoxifen followed by adjuvant anastrozole
(associated with 64% reduction in the risk of relapse in
the Boccardo study).
Advances in chemotherapy and target therapy
Papers presented at the meeting continue to highlight the
improvements in DFS and overall survival that can be
achieved in high-risk women when taxanes are added to
anthracycline-based therapy. AW Hutcheon presented an
update on the Aberdeen trial. Previously published results
from this study indicate that even patients who are
responding to an anthracycline-based neoadjuvant
chemotherapy regimen (cyclophosphamide, doxorubicin,
vincristine and prednisolone; CVAP) benefit from switch-
ing to docetaxel [4]. One hundred and four patients who
responded to neoadjuvant CVAP were randomized to
receive four additional cycles of CVAP or four cycles of
single-agent docetaxel before surgery. The pathologic
complete response rate in patients receiving docetaxel
was 34% compared with 16% for those continuing on
CVAP. With a median follow-up of 60months, patients
receiving docetaxel had improved DFS (90% versus 72%,
P=0.04) and overall survival (97% versus 78%, P=0.04).
Patients with node-positive breast cancer experience
greater benefit from adjuvant docetaxel, doxorubicin and
cyclophosphamide (TAC) than from 5-fluorouracil, doxoru-
bicin and cyclophosphamide, according to John Mackey
who updated previously presented results on behalf of the
Breast Cancer International Research Group [5]. At a
median follow-up of 55months, DFS and overall survival
favor the TAC arm. TAC resulted in a 28% reduction in the
risk of relapse (HR=0.72, P=0.0010) and a 30% reduc-
tion in the risk of death (HR=0.83, P=0.17). However,86
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subgroup analysis revealed that the benefit in DFS was
statistically significant only in the group with one to three
positive nodes. Patients had a reduced risk of death with
TAC treatment regardless of the Her2 status of their
primary tumors (Her2-positive HR=0.60, Her2-negative
HR=0.76). Cardiac toxicity did not seem prohibitive. Con-
gestive heart failure was seen in 1.6% of patients receiv-
ing TAC and in 0.5% of those receiving 5-fluorouracil,
doxorubicin and cyclophosphamide. One cardiac death
was seen in each arm of the study.
Information presented at the meeting may help medical
oncologists select which taxane to offer their patients.
Stephen Jones (US Oncology, Dallas, TX, USA) pre-
sented the results of a multicenter, randomized, phaseIII
comparison of docetaxel versus paclitaxel in 449women
with metastatic breast cancer. Docetaxel and paclitaxel
were dosed at 100mg/m2 and 175mg/m2 every 3weeks,
respectively. Docetaxel was associated with an overall
response rate of 32% versus 25% with paclitaxel
(P=0.10), and the duration of response was significantly
increased for the docetaxel group (7.5months versus
4.6months,  P<0.05). Time to progression favored the
docetaxel arm (4.6months versus 3.1months,
P<0.0001), as did median overall survival (15.4months
versus 12.7 months, P=0.03). This result was seen
despite the fact that approximately 25% of patients
crossed over to the other taxane after experiencing pro-
gressive disease and that the median survival after stop-
ping study of the drug was shorter for patients in the
docetaxel arm. This improvement in overall survival came
at the expense of greater toxicity. Febrile neutropenia was
seen in 15% of those treated with docetaxel but in only
2% of those treated with paclitaxel (P<0.05). Nonhema-
tologic toxicity was also greater in the docetaxel arm.
Additional clinical trials are needed to determine whether
nanoparticle albumin-bound paclitaxel (ABI-007) repre-
sents an important clinical advance. Joyce O’Shaughnessy
(US Oncology, Dallas, TX, USA) presented the results of a
comparison of ABI-007 (ABRAXANE™) and conventional
paclitaxel in 454patients with metastatic breast cancer.
Investigators in this multicenter trial administered ABI-007
without steroid premedication. The drug was well toler-
ated and patients receiving it had an improved response
rate as compared with conventional paclitaxel (21%
versus 10%, P=0.002) when assessed by independent
radiologic review. The time to progression also favored the
ABI-007 arm (21.9weeks versus 16.1weeks, P=0.029).
Jenny Chang (Breast Center, Baylor College of Medicine
and The Methodist Hospital, Houston, TX, USA) pre-
sented the results of a neoadjuvant study in locally
advanced breast cancer, designed to determine the effi-
cacy of single-agent neoadjuvant herceptin, to explore the
mechanism of action of herceptin and to determine bio-
markers of response. Twenty-seven patients with palpable
breast cancers were enrolled and received weekly her-
ceptin as single-agent therapy for 3weeks. Beginning in
week 4, docetaxel was added to the regimen. Tissue
specimens were available for study at the following time
points: pretreatment, day1, day8, day15 and day22.
None of the patients progressed during the herceptin
phase of the study and 26% had a partial response. Prolif-
eration, as assayed by Ki67, did not change with therapy
and high Ki67 correlated with resistance to therapy. Apop-
tosis was statistically increased with therapy even after
1week (from 2.6% to 4%). Chang believes that the syner-
gism seen with the combination of chemotherapy and her-
ceptin results from the fact that the two agents are
targeting different populations of malignant cells.
Changing the model for breast cancer care
Umberto Veronesi presented the William L McGuire
Memorial Lecture. His inspiring lecture described the revo-
lutionary change in clinical treatment philosophy from
‘maximum tolerable to minimum effective therapy’.
Veronesi described the clinical trials that have proven the
efficacy of breast-conserving surgery, of sentinel lymph
node mapping, of chemoprevention and of her2-targeted
therapy. He concluded that “we are achieving a reduction
in mortality while preserving a very good quality of life”.
Veronesi urged patients and clinicians to continue clinical
trials evaluating gene expression profiling and partial
breast radiation as these techniques may further decrease
the amount of therapy required by selected patients.
Advances in breast radiation therapy designed to
decrease both the time required to complete treatment
and the morbidity associated with it were presented in a
mini-symposium. Jayant Vaidya presented preliminary
results from the ongoing targeted intra-operative radiother-
apy (TARGIT) trial [6]. Frank Vicini discussed the multiple
ways in which partial breast radiation can be delivered,
and highlighted the upcoming trial planned by the National
Surgical Adjuvant Breast and Bowel Project to compare
whole breast radiation and three different techniques of
partial breast radiation (catheter or balloon [MammoSite]
brachytherapy, or three-dimensional conformal external
beam radiation).
Conclusion
The 26th San Antonio Breast Cancer Symposium contin-
ues to bring together clinical and basic investigators from
all over the world. Presentations at this year’s meeting
expand our treatment options for those who are diag-
nosed with benign and/or malignant disease. The
meeting provides a unique forum with integration of clini-
cal and basic research presentations. Each attendee is
challenged to translate the data presented into scientific
hypotheses that will further enhance our understanding of
the disease.87
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